Showing results (121-130 of 157) with videos related to

Sort By:
Pageof 16
JAMA Oncology|June 26, 2020
Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 TrialJavier Cortés, Véronique Diéras, Sylvie Lorenzen, et al.
Frontiers in Oncology|November 22, 2021
First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 StudySonia Pernas, Patricia Villagrasa, Ana Vivancos, et al.
Molecular Oncology|May 29, 2021
Gene expression profiles of breast cancer metastasis according to organ siteFara Brasó-Maristany, Laia Paré, Nuria Chic, et al.
BMC Infectious Diseases|July 30, 2025
Impact of post-COVID-19 syndrome on quality of life and functionality in ethnically diverse and vulnerable populations in the AmazonMarcelo Silva de Paula, Sheyla Mara Silva de Oliveira, Tatiane Costa Quaresma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2021
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based TherapyTomás Pascual, Aranzazu Fernandez-Martinez, Maki Tanioka, et al.
Scientific Reports|July 11, 2024
Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancerNatàlia Lorman-Carbó, Olga Martínez-Sáez, Aranzazu Fernandez-Martinez, et al.
Ebiomedicine|June 23, 2021
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapyNuria Chic, Francesco Schettini, Fara Brasó-Maristany, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2025
Elacestrant in Women with Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE TrialMaria Vidal, Claudette Falato, Tomás Pascual, et al.
NPJ Breast Cancer|February 10, 2026
Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxaneMarcin Kubeczko, Sandra Cobo, Rodrigo Sanchez-Bayona, et al.
Frontiers in Oncology|May 21, 2019
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast CancerTomás Pascual, Miguel Martin, Aranzazu Fernández-Martínez, et al.
Pageof 16